FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286293844> ?p ?o ?g. }

• W4286293844 endingPage "e13015" @default.
• W4286293844 startingPage "e13015" @default.
• W4286293844 abstract "e13015 Background: Eribulin is a non-taxane microtubule inhibitor, which was approved for the third-line treatment of advanced breast cancer (ABC) in China in 2019. However, the efficacy and safety data of eribulin for the ABC in Chinese patients is lacking, whether as first, second, or third-line regimens. This study aimed to evaluate the clinical effectiveness, safety, and treatment pattern of eribulin in first to third-line settings in Chinese ABC patients. Methods: Patients with histologically confirmed advanced breast cancer, who previously received ≤2 lines of treatment for metastatic disease were enrolled. In HR+/HER2- ABC, eribulin monotherapy was used; in HER2+ ABC, eribulin plus anti-HER2 targeted therapy were used; in metastasis triple-negative breast cancer (mTNBC), eribulin plus immunotherapy/chemotherapy were used. Primary outcome was progression-free survival (PFS). Secondary outcomes included disease control rate (DCR) and safety. This study was approved by the SYSMH and SYSUCC Ethics Committee (approval No. 2020-KY-064). Results: Forty-seven patients were enrolled from 2021.1.1 to 2021.10.20, including 41 metastatic and 6 de novo ABC patients. Eribulin was used as first-line therapy in 12 (25.5%) patients, second-line therapy in 24 patients (51.1%), and third-line therapy in 11 (23.1%) patients. More than 90% of the patients did not receive gemcitabine or vinorelbine, and 30.0% of them did not receive anthracycline or taxane previously. DCR was 70.2%, as 24 cases (51.1%) had stable disease and 9 cases (19.1%) had complete or partial remission. In subgroup analysis, median PFSs of 9.6 (95% CI: 6.5-12.7), 7.1 (95%CI: 4.4-9.8), and 5.6 (95%CI: 3.8-7.5) months were observed in patients receiving eribulin as first-, second-, and third-line therapy, respectively. In addition, median PFSs were 7.1 (95% CI: 5.1-9.3), 9.6 (95%CI: 3.6-15.7), 4.6 (95%CI: 4.6-4.6) and 5.8 (95%CI: 4.4-7.3) months for HR+/HER2-, HR+/HER2+, HR-/HER2+, and mTNBC patients, respectively. Other results from the subgroups analysis were shown in table. Common treatment-related toxicity was hematological toxicities including leukopenia (23%), neutropenia (17%), and thrombocytopenia (10%). There was no ≥grade 3 adverse events and no adverse event-related treatment discontinuation. Conclusions: Eribulin monotherapy or combined with targeted therapy was effective and well-tolerated as the first to third lines of treatment in ABC. This promising therapeutic outcome might warrant further studies in early eribulin administration in ABC patients. Clinical trial information: NCT04683445. [Table: see text]" @default.
• W4286293844 created "2022-07-21" @default.
• W4286293844 creator A5000376876 @default.
• W4286293844 creator A5003329103 @default.
• W4286293844 creator A5006325289 @default.
• W4286293844 creator A5018863416 @default.
• W4286293844 creator A5053218462 @default.
• W4286293844 creator A5056065058 @default.
• W4286293844 creator A5062305863 @default.
• W4286293844 creator A5077581291 @default.
• W4286293844 creator A5082613642 @default.
• W4286293844 date "2022-06-01" @default.
• W4286293844 modified "2023-10-16" @default.
• W4286293844 title "Effectiveness and safety of eribulin as a front-line treatment in advanced breast cancer patients in China: A prospective real-world study." @default.
• W4286293844 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.e13015" @default.
• W4286293844 hasPublicationYear "2022" @default.
• W4286293844 type Work @default.
• W4286293844 citedByCount "0" @default.
• W4286293844 crossrefType "journal-article" @default.
• W4286293844 hasAuthorship W4286293844A5000376876 @default.
• W4286293844 hasAuthorship W4286293844A5003329103 @default.
• W4286293844 hasAuthorship W4286293844A5006325289 @default.
• W4286293844 hasAuthorship W4286293844A5018863416 @default.
• W4286293844 hasAuthorship W4286293844A5053218462 @default.
• W4286293844 hasAuthorship W4286293844A5056065058 @default.
• W4286293844 hasAuthorship W4286293844A5062305863 @default.
• W4286293844 hasAuthorship W4286293844A5077581291 @default.
• W4286293844 hasAuthorship W4286293844A5082613642 @default.
• W4286293844 hasConcept C121608353 @default.
• W4286293844 hasConcept C126322002 @default.
• W4286293844 hasConcept C143998085 @default.
• W4286293844 hasConcept C2775930923 @default.
• W4286293844 hasConcept C2776387010 @default.
• W4286293844 hasConcept C2776694085 @default.
• W4286293844 hasConcept C2776802502 @default.
• W4286293844 hasConcept C2777511904 @default.
• W4286293844 hasConcept C2778239845 @default.
• W4286293844 hasConcept C2780258809 @default.
• W4286293844 hasConcept C2780350996 @default.
• W4286293844 hasConcept C530470458 @default.
• W4286293844 hasConcept C71924100 @default.
• W4286293844 hasConceptScore W4286293844C121608353 @default.
• W4286293844 hasConceptScore W4286293844C126322002 @default.
• W4286293844 hasConceptScore W4286293844C143998085 @default.
• W4286293844 hasConceptScore W4286293844C2775930923 @default.
• W4286293844 hasConceptScore W4286293844C2776387010 @default.
• W4286293844 hasConceptScore W4286293844C2776694085 @default.
• W4286293844 hasConceptScore W4286293844C2776802502 @default.
• W4286293844 hasConceptScore W4286293844C2777511904 @default.
• W4286293844 hasConceptScore W4286293844C2778239845 @default.
• W4286293844 hasConceptScore W4286293844C2780258809 @default.
• W4286293844 hasConceptScore W4286293844C2780350996 @default.
• W4286293844 hasConceptScore W4286293844C530470458 @default.
• W4286293844 hasConceptScore W4286293844C71924100 @default.
• W4286293844 hasIssue "16_suppl" @default.
• W4286293844 hasLocation W42862938441 @default.
• W4286293844 hasOpenAccess W4286293844 @default.
• W4286293844 hasPrimaryLocation W42862938441 @default.
• W4286293844 hasRelatedWork W1967350504 @default.
• W4286293844 hasRelatedWork W2288325587 @default.
• W4286293844 hasRelatedWork W2356028434 @default.
• W4286293844 hasRelatedWork W2357571516 @default.
• W4286293844 hasRelatedWork W2388022328 @default.
• W4286293844 hasRelatedWork W2436215013 @default.
• W4286293844 hasRelatedWork W2561432271 @default.
• W4286293844 hasRelatedWork W2592215987 @default.
• W4286293844 hasRelatedWork W2908131653 @default.
• W4286293844 hasRelatedWork W4286293844 @default.
• W4286293844 hasVolume "40" @default.
• W4286293844 isParatext "false" @default.
• W4286293844 isRetracted "false" @default.
• W4286293844 workType "article" @default.